~186Re-Etidronate: Efficacy of palliative radionuclide therapy for painful bone metastases

摘要

Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encour- aging clinical results of palliative therapy using ~186Re- HEDP, with an overall reported response rate of ±71 /100 for Painful osseous metastasized prostate and breast cancer Patients. ~186Re-HEDP is a very potential isotope with Numerous advantageous characteristics for this purpose.